AGIOS PHARMACEUTICALS, INC.AGIOEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 10.02% | 5.6M | ▲ +0.13pp | 2024-02-12 |
| BlackRock, Inc. | 8.90% | 5.0M | — | 2024-01-25 |
| BB Biotech AG | 7.20% | 4.0M | — | 2024-02-13 |
| STATE STREET CORPORATION | 4.70% | 847 | — | 2024-01-22 |
| Wellington Management Group LLP | 3.95% | 2.2M | — | 2023-11-09 |
| Armistice Capital, LLC | 3.88% | 2.2M | ▼ -2.43pp | 2024-11-14 |
| Rock Springs Capital Management LP | 3.85% | 2.2M | — | 2024-02-14 |
| Farallon Capital Partners, L.P. | 0.70% | 422.5K | ▲ +0.10pp | 2024-11-08 |
Insider Transactions
Net 90d: −$2.52M · buys $0 / sells $2.52MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-02 | Burns James William | Chief Legal Officer | Option exercise | 8.5K | $0.00 | $0 |
| 2026-04-02 | Burns James William | Chief Legal Officer | Sell (open market) | 3.3K | $34.71 | $113.8K |
| 2026-04-02 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Option exercise | 8.1K | $0.00 | $0 |
| 2026-04-02 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sell (open market) | 3.0K | $34.71 | $102.7K |
| 2026-04-02 | Tsveta Milanova | Chief Commercial Officer | Option exercise | 8.5K | $0.00 | $0 |
| 2026-04-02 | Tsveta Milanova | Chief Commercial Officer | Sell (open market) | 3.3K | $34.71 | $113.2K |
| 2026-04-02 | Cecilia Jones | Chief Financial Officer | Option exercise | 8.5K | $0.00 | $0 |
| 2026-04-02 | Cecilia Jones | Chief Financial Officer | Sell (open market) | 3.1K | $34.71 | $109.0K |
| 2026-04-02 | Brian Goff | Chief Executive Officer | Option exercise | 25.5K | $0.00 | $0 |
| 2026-04-02 | Brian Goff | Chief Executive Officer | Sell (open market) | 12.5K | $34.71 | $432.9K |
1–10 of 55
Page 1 / 6